Upsher-Smith releases Doxazosin tablets

Print Friendly, PDF & Email

MAPLE GROVE, Minn. — Upsher-Smith Laboratories, LLC (Upsher-Smith) announced the launch of Doxazosin tablets, USP, 1 mg, 2 mg, 4 mg and 8 mg.

The product was approved by the U.S. Food and Drug Administration (FDA) on April 17, 2018. Upsher-Smith’s Doxazosin tablets are an AB-rated generic version of the branded product, Cardura (doxazosin mesylate tablets).

The doxazosin tablet market had U.S. sales of approximately $51.2 million for the 12 months ending January, 2018 according to IQVIA.



Comments are closed.